Predictors of in hospital mortality in cardiogenic shock following ST-elevation myocardial infarction (STEMI)

Document Type : original articles

Authors

Yazd Cardiovascular Research Center, Non- communicable Diseases Research Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

Abstract

Objectives: Cardiogenic shock (CS) is a severe complication of ST-Elevation Myocardial Infarction (STEMI) and is associated with high mortality rates. This study aimed to identify predictors of in-hospital mortality in patients experiencing cardiogenic shock following STEMI.

Methods: A retrospective cohort study was conducted at Afshar Hospital in Yazd from 2018 to 2023, analyzing clinical data from 62 STEMI patients diagnosed with CS. The mean age of the cohort was 64.9 ± 13.5 years, with a male predominance of 69.5%. Key variables assessed included left ventricular ejection fraction (LVEF), comorbidities, and treatment interventions. Survival analysis and Cox regression were employed to evaluate mortality outcomes.

Results: LVEF less than 30% emerged as a significant predictor of in-hospital mortality, with a hazard ratio of 11.1 (95% CI: 2.6–47.4; p < 0.001). The mean survival time was 7.0 days (95% CI: 5.8–8.3). Additionally, hyperlipidemia was associated with increased mortality, presenting an odds ratio of 11.3 (95% CI: 1.1–114.1; p = 0.040). The prevalence of chronic kidney disease was notably higher in the deceased cohort (28.0% vs. 8.1%; p = 0.042). Although urgent percutaneous coronary intervention (PCI) was performed in the majority of cases, mortality remained significant.

Conclusions: This study highlights that LVEF and hyperlipidemia are critical predictors of in-hospital mortality in patients with cardiogenic shock following STEMI. Other studies also suggest the prognostic value of LVEF in various cardiac conditions, particularly in the context of acute coronary syndromes [14, 15]. Also, the combination of renal dysfunction left ventricular ejection fraction, and advanced age has been proposed as a predictor of in-hospital mortality [18]. These findings underscore the importance of early identification and targeted management strategies to improve patient outcomes in this high-risk population.

Keywords

Main Subjects

References

1.Laghlam D, Benghanem S, Ortuno S, et al.Management of cardiogenic shock: a narrative review. Ann Intensive Care. 2024;14(1):45.
2.Alkhunaizi FA, Smith N, Brusca SB, et al. The Management of Cardiogenic Shock From Diagnosis to Devices: A Narrative Review. CHEST Crit Care. 2024(2):100071.
3.Samsky MD, Morrow DA, Proudfoot AG, et al. Cardiogenic Shock After Acute Myocardial Infarction: A Review. JAMA. 2021;326(18):1840-1850.
4.Shirakabe A, Matsushita M, Shibata Y, et al. Organ dysfunction, injury, and failure in cardiogenic shock. J Intensive Care. 2023;11(1):26.
5.Kologrivova I, Kercheva M, Panteleev O, et al. The Role of Inflammation in the Pathogenesis of Cardiogeninic Shock Secondary to Acute Myocardial Infarction: A Narrative Review. Biomedicines. 2024;12(9):2073.
6.Blumer V, Kanwar MK, Barnett CF, et al. Cardiogenic Shock in Older Adults: A Focus on Age-Associated Risks and Approach to Management: A Scientific Statement From the American Heart Association. Circulation. 2024;149(14):e1051-e1065.
7.Almendro-Delia M,Núñez-Gil IJ, Lobo M, et al.Short- and Long-Term Prognostic Relevance of Cardiogenic Shock in Takotsubo Syndrome:Results From the RETAKO Registry. JACC Heart Fail. 2018;6(11):928-936.
8.Sundermeyer J, Kellner C, Beer BN, et al. Association between left ventricular ejection fraction, mortality and use of mechanical circulatory support in patients with non-ischaemic cardiogenic shock. Clin Res Cardiol. 2024;113(4):570-580.
9.Tyler JM, Brown C, Jentzer JC, et al.Variability in reporting of key outcome predictors in acute myocardial infarction cardiogenic shock trials.Catheter Cardiovasc Interv.2022;99(1):19-26.
10.Tehrani BN, Truesdell AG, Psotka MA, et al.A Standardized and Comprehensive Approach to the Management of Cardiogenic Shock. JACC Heart Fail. 2020;8(11): 879-891.
11.Thiele H, de Waha-Thiele S, Freund A, et al.Management of cardiogenic shock. EuroIntervention.2021;17(6):451-465.
12.Harjola VP, Lassus J, Sionis A, et al.Clinical picture and risk prediction of short-term mortality in cardiogenic shock. Eur J Heart Fail. 2015;17(5):501-9.
13.Taha HS, Gohar A, Ammar W, et al.Predictors of short-term mortality in cardiogenic shock: insights from an Egyptian multicenter registry. Egypt Heart J. 2024;76(1):94.
14.Sciaccaluga C, Mandoli GE, Ghionzoli N, et al. Risk stratification in cardiogenic shock: a focus on the available evidence. Heart Fail Rev. 2022;27(4):1105-1117.
15.Ostadal P, Belohlavek J.What is cardiogenic shock? New clinical criteria urgently needed. Curr Opin Crit Care. 2024;30(4):319-323.
16.Forner J, Schupp T, Weidner K, et al. Effect of Cardiovascular Risk Factors on 30-Day All-Cause Mortality in Cardiogenic Shock. J Clin Med. 2023;12(14):4870.
17.Jin J, Shi Z, Pang X. Association between low-density lipoprotein cholesterol level and mortality in patients with cardiogenic shock: a retrospective cohort study. BMJ Open. 2021;11(7):e044668.
18.Çinar T, Hayiroğlu Mİ, Şeker M, et al.The predictive value of age, creatinine, ejection fraction score for in-hospital mortality in patients with cardiogenic shock. Coron Artery Dis. 2019;30(8):569-574.
19.Hochman JS,Sleeper LA,Webb JG, et al.Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med. 1999;341(9):625-34.
20.White HD, Assmann SF, Sanborn TA, et al.Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial. Circulation. 2005;112(13):1992-2001.
21.Mehta RH, Lopes RD, Ballotta A, et al. Percutaneous coronary intervention or coronary artery bypass surgery for cardiogenic shock and multivessel coronary artery disease? Am Heart J. 2010;159(1);141-7.
22.Senman B, Jentzer JC, Barnett CF, et al. Need for a Cardiogenic Shock Team Collaborative-Promoting a Team-Based Model of Care to Improve Outcomes and Identify Best Practices. J Am Heart Assoc. 2024;13(6):e031979.
23.Shaefi S, O'Gara B, Kociol RD, et al. Effect of cardiogenic shock hospital volume on mortality in patients with cardiogenic shock. J Am Heart Assoc. 2015;4(1); e001462.
24.Pöss J, Köster J, Fuernau G, et al. Risk stratification for patients in cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol. 2017; 69(15):1913-1920.
25.Patarroyo Aponte MM, Manrique C, Kar B. Systems of care in cardiogenic shock. Methodist Debakey Cardiovasc J. 2020;16(1):50-56.
26.Basir MB, Kapur NK, Patel K, et al. Improved outcomes associated with the use of shock protocols: updates from the National Cardiogenic Shock Initiative. Catheter Cardiovasc Interv.2019;93(7):1173-1183.
27.Jentzer JC, Tabi M, Wiley BM, et al. Echocardiographic correlates of mortality among cardiac intensive care unit patients with cardiogenic shock. Shock.2022; 57(3):336-343.
28.McLean AS.Echocardiography in shock management. Crit Care. 2016;20:275.
29.Lemor A, Basir MB, Patel K, et al. Multivessel versus culprit-vessel percutaneous coronary intervention in cardiogenic shock . JACC Cardiovas Interv.2020; 13(10):1171 -1178.
30.Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/ American Heart Association Joint Committee on Clinical Practice Guidelines.  Circulation.2022; 145(3): e18-e114.
Cardiovascular Biomedicine
Volume 4, Issue 2
December 2024
Pages 44-53

Files

History

  • Receive Date: 11 November 2024
  • Revise Date: 22 January 2025
  • Accept Date: 23 January 2025

Share

How to cite

Statistics